These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34217971)

  • 1. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.
    Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
    Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
    Bergeron A; MacGrogan G; Bertaut A; Ladoire S; Arveux P; Desmoulins I; Bonnefoi H; Loustalot C; Auriol S; Beltjens F; Degrolard-Courcet E; Charon-Barra C; Richard C; Boidot R; Arnould L
    Mod Pathol; 2021 Jul; 34(7):1282-1296. PubMed ID: 33753865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
    Zhang Y; Luo X; Chen M; Yang L; Lei T; Pu T; Wei B; Bu H; Zhang Z
    Breast Cancer Res Treat; 2022 Jul; 194(2):279-295. PubMed ID: 35666367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Djerroudi L; El Sabeh-Ayoun A; Benoist C; Pierron G; Masliah-Planchon J; Fuhrmann L; Kieffer Y; Carton M; Ramtohul T; Callens C; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
    Mod Pathol; 2024 May; 37(5):100463. PubMed ID: 38428737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
    Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
    J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
    Christgen M; Geffers R; Kreipe H; Lehmann U
    Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.
    Weigelt B; Geyer FC; Natrajan R; Lopez-Garcia MA; Ahmad AS; Savage K; Kreike B; Reis-Filho JS
    J Pathol; 2010 Jan; 220(1):45-57. PubMed ID: 19877120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
    Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
    Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
    Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
    Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
    Grote I; Bartels S; Christgen H; Radner M; Gronewold M; Kandt L; Raap M; Lehmann U; Gluz O; Graeser M; Kuemmel S; Nitz U; Harbeck N; Kreipe H; Christgen M
    Mod Pathol; 2022 Dec; 35(12):1804-1811. PubMed ID: 35842479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
    Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
    Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.